Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Implantable Catalyst Against Cancer

By Mark Bradley, University of Edinburgh | November 16, 2016

(Photo credit: The NanoRobotics Laboratory, Polytechnique Montreal)

Biocompatible heterogeneous copper catalyst for click chemistry in living organisms.

Assembling a drug from harmless components at the target location, such as a tumor, would help reduce the side effects of treatment. In the journal Angewandte Chemie, British and Malaysian scientists present a new, nontoxic catalyst made of copper nanoparticles that can be used to specifically and selectively assemble building blocks in a living system. It was shown to be possible to make an anti-tumor drug from two benign components in situ.

Chemical reactions that do not interfere with cellular processes are important in the investigation of biological functions in the native environment. The approach known as “click” chemistry makes it possible to carry out selective and highly specific reactions that are easy to carry out, even in a complex environment. In this method, molecules are “clicked” together (similar to snapping a puzzle together).

An example of such a reaction is the azide-alkyne cycloaddition reaction (reported by Meldal and Sharpless), in which an azido group (-N(3)) reacts specifically with an alkyne group (-CC-) to form a triazole, a five-membered ring with three nitrogen and two carbon atoms linked by a double bond. This reaction is often used to link biomolecules, though it has previously not been suitable for use in living systems because the copper ions required as catalyst are toxic.

A new, nontoxic catalyst now makes this reaction available for new areas of application. It was developed by a team from the University of Edinburgh (Chemistry and the Queen’s Medical Research Institute, U.K.) and the Universiti Kebansaan Malaysia, and consists of nanoparticles of copper bound into a polymer resin.

The team successfully tested the new catalyst in biological systems ranging from cells to zebrafish. The first test used a dye that fluoresces only when two components are linked through the “click reaction”. In order to prove the biocompatibility of the catalyst, the researchers implanted a copper-resin sphere into the yolk sacs of zebrafish embryos that subsequently developed normally to the larval stage. After the dye precursors were added to the water, the larvae began to fluoresce, demonstrating that the catalyst is also effective as an implant.

For more tests, the researchers broke the anti-tumor drug Combretastatin A-4 (CA-4) into two halves, equipping one with an azido group, the other with an alkyne. By using the new catalyst, the halves could be attached through the resulting triazole ring. While both of the pieces are nontoxic, the CA-4 triazole product stopped the cell growth of cultivated tumor cells and initiated programmed cell death.

It may be possible to implant the copper-resin spheres into the proximity of a tumor and then use them to generate active drugs from inactive precursors on location. This would limit the cytotoxic effects to the tumor itself.

(Mark Bradley, the author, is a professor at the School of Chemistry and the Queen’s Medical Research Institute at the University of Edinburgh. He is a recipient of multiple awards, and the co-founder of three active university spinouts. His research interests span from chemical biology and optical imaging, to development of biomaterials for stem cell modulation and beyond.)

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50